Supernus Pharma To Acquire Adamas Pharma For Total Consideration Up To $9.10/shr

(RTTNews) - Supernus Pharmaceuticals Inc. (SUPN) agreed to acquire Adamas Pharmaceuticals Inc. (ADMS) for total consideration up to $9.10 per share. The acquisition is expected to be significantly accretive in 2022.

As per the terms of the agreement, Supernus will commence a tender offer to acquire all outstanding shares of Adamas Pharmaceuticals for a purchase price of $8.10 per share in cash or an aggregate of approximately $400 million payable at closing plus two non-tradable CVRs. All cash consideration will be funded through existing balance sheet cash.

The CVR entitles Adamas stockholders to receive up to an additional $1.00 per share in cash payable upon GOCOVRI achieving certain net sales milestones within specified periods.

The transaction, which has been approved by the boards of directors of both companies, is expected to close in late fourth quarter 2021 or in early first quarter 2022.